BIOVISION, organised by the Fondation pour l’Université de Lyon will take place at the Cité Internationale in Lyon, France, on April 15 and 16, 2015. The forum is now in it’s 10th year, hosting over 1,500 attendees from the international health care and life sciences sector. It will features key players from academia, civil society and the public and private sectors.
BIOVISION has chosen to support innovation and entrepreneurship via its wealth of programs and events because of a strong desire to move beyond discussion to action in a world that is under threat from epidemics and the increasing incidence of cancers, diabetes and cardiovascular diseases. It is intended as a launch pad for promising health care entrepreneurs who own biotech, medtech or e-health companies and are seeking to establish valuable contacts with investors and industry representatives.
The partner events for healthcare entrepreneurship and innovation includes BIOVISION Next – TWAS, Wednesday, April 15, from 9 a.m. to 1 p.m: BIOVISION Next, developed in close collaboration with The World Academy of Sciences (TWAS), is a grant programme that helps young scientists attend the BIOVISION forum. This year, the BIOVISION Next program will give 24 young researchers, selected by TWAS, the chance to present their projects at this special session.
EBE (European Biopharmaceutical Enterprises) will be hosting a session on Wednesday, April 15, 2015 from 2 p.m. to 3.45 p.m, EBE will also celebrates its 15th anniversary at BIOVISION.
The session 'Europe's Emerging Science: Putting Advanced Therapies for Better Health into Practice,' will feature Eduardo Bravo, chairman and chief executive officer of TiGenix; Andrea Chiesi, director of R&D portfolio management at Chiesi Farmaceutici; Paolo Macchiarini, associate professor in the department of clinical science, Intervention and Technology at Sweden’s Karolinksa Institute; Sander Van Deventer, member of the Board of UniQure; and Faraz Kermani from the European Federation of Pharmaceutical Industries and Associations (EFPIA), will act as moderator.
Future-oriented sessions will cover overall health and personalised medicine, with leading speakers- Professor Leroy Hood from the Institute for System Biology (USA); Professor Guillaume Beslon, of INRIA (Inventors for the Digital World); Dr Pascal Sempé, representing IBM; Dr Alain Beaudet, chief executive of the Canadian Institutes of Health Research; Agnès Buzyn, director of INCa (France’s national cancer institute); Professor Peter Openshaw of Imperial College, London; Greg Perry from the Medicine Patent Pool; Professor Ole Petter Ottersen, president of the University of Oslo, Norway
BIOVISION also features networking and partnership opportunities via the online platform and one-to-one meeting areas on site A public session on 'Global and personalized health, how to ensure a worldwide benefit?' will be Thursday April 16, 2015 from 11am to 12.30 pm.